肺癌方联合化疗在痰瘀互结型肺癌临床治疗中的应用对患者机体免疫能力的改善分析  

Analysis of the Improvement of Patients’ Immunity by the Application of Lung Cancer Formula Combined with Chemotherapy in the Clinical Treatment of Cancer of Phlegm-stasis Interconnection Type

作　　者：肖恺 邵红伟 XIAO Kai;SHAO Hongwei(Department of Oncology,Taizhou City Hospital of Traditional Chinese Medicine,Taizhou,Jiangsu Province,225300 China;Taizhou Hospital of Integrative Medicine,Taizhou,Jiangsu Province,225300 China)

机构地区：[1]江苏省泰州市中医院肿瘤科,江苏泰州225300 [2]江苏省泰州市中西医结合医院,江苏泰州225300

出　　处：《系统医学》2022年第21期50-53,57,共5页Systems Medicine

基　　金：超声靶向透药科技在骨性关节炎的临床研究(TZ202112)。

摘　　要：目的研究痰瘀互结型肺癌患者行肺癌方联合化疗治疗的效果。方法选取泰州市中医院2021年1—12月收治的128例痰瘀互结型肺癌患者,按照双盲法分常规组和科研组,各64例。常规组行常规化疗方案,科研组在常规组基础上联合肺癌方,比较两组疗效、中医证候积分、免疫指标、不良反应发生情况。结果治疗后,科研组中医证候积分较常规组低,CD3^(+)、CD4^(+)/CD8^(+)值较常规组更高,CD8^(+)值较常规组更低,差异有统计学意义(P<0.05);科研组有效率为95.31%,高于常规组的84.38%,科研组不良反应发生率为6.25%,低于常规组的18.75%,差异有统计学意义(χ^(2)=4.195、4.571,P<0.05)。结论肺癌方联合化疗治疗痰瘀互结型肺癌患者可调节免疫、减缓不适程度,增强疗效、保证用药安全。Objective To study the effect of lung cancer formula combined with chemotherapy treatment in patients with lung cancer of phlegm-stasis interconnection type. Methods The data were obtained from 128 patients with lung cancer with phlegm-stasis from January to December 2021 admitted to Taizhou Traditional Chinese Medicine Hospital. The double-blind method was divided into conventional group and research group, 64 cases in each group. The conventional group conventional chemotherapy regimen, the research group base on the conventional group add lung cancer formula. The efficacy, TCM syndrome score, immune index and occurrence of adverse reactions were compared between the two groups. Results After treatment, TCM syndrome scores in the research group were lower than those in the conventional group, the values of CD3^(+), CD4^(+)/CD8^(+) were higher than those in the conventional group, and the values of CD8^(+) were lower, the difference was statistically significant(P<0.05). The effective rate of the research group was 95.31% higher than that of the conventional group(84.38%), and the adverse reaction rate of the research group was 6.25% lower than that of the conventional group(18.75%), the difference was statistically significant(χ^(2)=4.195,4.571, P<0.05). Conclusion Lung cancer formula combined with chemotherapy can regulate immunity, reduce discomfort, enhance efficacy, and ensure drug safety in the treatment of lung cancer patients with phlegm-stasis interconnection, which is worthy of promotion.

关 键 词：肺癌方 化疗 痰瘀互结型肺癌 中医证候积分 免疫能力 疗效 

分 类 号：R734.2[医药卫生—肿瘤]